Trial
NCT00903461
Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Pittsburgh
Collaborators
National Cancer Institute (NCI)
Condition
Carcinoma, Squamous Cell of Head and Neck
Intervention
EGFR Antisense DNA
Why stopped
drug supply issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-15